Novartis washes its hands of another bispecific at the center of $2.5B Xencor deal

Max Gelman

Senior Editor

A centerpiece of Novartis’ $2.5 billion bispecifics deal with Xencor has been sidelined, the California biotech said in its third quarter earnings report Monday. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis washes its hands of another bispecific at the center of $2.5B Xencor deal

Max Gelman

Senior Editor

Sign up to read this article for free.

Senior AstraZeneca exec detained in China amid wider investigation

Avid Bioservices to be sold to private equity firms for $1.1B

Pfizer to invest $1B in China over next five years — reports

Soft RSV sales reveal a vaccine market failing to catch post-Covid momentum

Stephen Squinto's JPM life sciences team is raising a new fund for later-stage companies

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

No­var­tis wash­es its hands of an­oth­er bis­pe­cif­ic at the cen­ter of $2.5B Xen­cor deal

Max Gelman

Senior Editor

Sign up to read this article for free.

Se­nior As­traZeneca ex­ec de­tained in Chi­na amid wider in­ves­ti­ga­tion

Avid Bioser­vices to be sold to pri­vate eq­ui­ty firms for $1.1B

Pfiz­er to in­vest $1B in Chi­na over next five years — re­ports

Soft RSV sales re­veal a vac­cine mar­ket fail­ing to catch post-Covid mo­men­tum

Stephen Squin­to's JPM life sci­ences team is rais­ing a new fund for lat­er-stage com­pa­nies

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Novartis washes its hands of another bispecific at the center of $2.5B Xencor deal

Senior AstraZeneca exec detained in China amid wider investigation

Avid Bioservices to be sold to private equity firms for $1.1B

Pfizer to invest $1B in China over next five years — reports

Soft RSV sales reveal a vaccine market failing to catch post-Covid momentum

Stephen Squinto's JPM life sciences team is raising a new fund for later-stage companies

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks